Table 2.
TAR RNA | Ligand source | Ligand scaffold | Method | PDB codes | Refs. |
---|---|---|---|---|---|
BIV | BIV Tat (68–81) | Peptide | NMR | 1mnb | 73 |
BIV | BIV Tat (65–81) | Peptide | NMR | 1biv | 75 |
BIV | BIV Tat-derived peptide | Cyclic peptide | NMR | 2a9x | 82 |
BIV | JDV Tat ARM | Peptide | NMR | 1zbn | 155 |
EIAV | EIAV CycT1-Tat | Protein complex | X-ray | 2w2h | 135 |
HIV-1 | Designed Tat mimic L-22 | Cyclic peptide | NMR | 2kdq | 70 |
HIV-2 | Lead compound | Arginine-pyrimidine tripeptide | NMR | 2kmj | 32 |
HIV-1 | Designed Tat mimic KPZ-41 | Cyclic peptide | NMR | 2kx5 | 62 |
HIV-1 | L-22 (low population) | Cyclic peptide | NMR | 5j2w | 67 |
HIV-1 | HIV-1 Tat (1–49)-SEC | Protein complex | X-ray | 5l1z | 68 |
HIV-1 | HIV-1 Tat (1–49)-SEC | Protein complex | X-ray | 6cyt | 139 |
HIV-1 | TBP6.7 | Lab-evolved protein | X-ray | 6cmn | 77 |
HIV-2 | HIV-1 Tat (44–60) | Peptide | NMR | 6mce | 76 |
HIV-1 | Designed Tat mimic JB181 | Cyclic peptide | NMR | 6d2u | 63 |